With respect to AML-MR, ICC separates this entity into AML with MR gene mutations (here including RUNX1) and with MR cytogenetic abnormalities, with mutations having the higher hierarchy. This evidence concerns the gene RUNX1 and intrahepatic cholangiocarcinoma.